Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Clinical Pearls: Results
Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated chronic lymphocytic leukemia (CLL).
- Idelalisib + rituximab demonstrated an improvement in progression-free survival (PFS) compared with placebo + rituximab [HR = 0.15]
- Median PFS was not reached in idelalisib arm and was 5.5 months in placebo arm
- Overall survival benefit was also identified in idelalisib arm
Clinical Pearls: Adverse Events
- There was a decrease in the risk of infusion reaction in the idelalisib arm
- 6 patients in the idelalisib arm experienced transaminitis
- In this analysis, patients treated with idelalisib did not see an increased risk of diarrhea
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
